A carregar...
iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
BACKGROUND. Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia, weight gain, or other objections may lead to clinical inertia, whereby therapy is not intensified and patients live with uncontrolled...
Na minha lista:
| Publicado no: | Diabetes Spectr |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Diabetes Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5951239/ https://ncbi.nlm.nih.gov/pubmed/29773934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/ds17-0014 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|